Therapeutic Advances for Huntington’s Disease
Open accessThe DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a progressive neurological disease that is inherited in an autosomal fashion. The cause of disease pathology is an expansion of cytosine-adenine-guanine (CAG) repeats within the huntingtin gene (HTT) on chromosome 4 (4p16.3), which codes the huntingtin protein (mHTT). The common symptoms of HD include motor and cognitive impairment of psychiatric functions. Patients exhibit a representative phenotype of involuntary movement (chorea) of limbs, impaired cognition, and severe psychiatric disturbances (mood swings, depression, and personality changes). A variety of symptomatic treatments (which target glutamate and dopamine pathways, caspases, inhibition of aggregation, mitochondrial dysfunction, transcriptional dysregulation, and fetal neural transplants, etc.) are available and some are in the pipeline. Advancement in novel therapeutic approaches include targeting the mutant huntingtin (mHTT) protein and the HTT gene. New gene editing techniques will reduce the CAG repeats. More appropriate and readily tractable treatment goals, coupled with advances in analytical tools will help to assess the clinical outcomes of HD treatments. This will not only improve the quality of life and life span of HD patients, but it will also provide a beneficial role in other inherited and neurological disorders. In this review, we aim to discuss current therapeutic research approaches and their possible uses for HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439 · cited 1×
“It is the principal factor for the manifestation of HD because aggregates are never a remarkable feature in the brain of normal subjects [26,27].”
BackgroundRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“Rapamycin Aggregation mammalian target of rapamycin (mTOR) inhibitor Showed efficacy in a rodent model [54,55]”
BackgroundBates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374 · cited 1×
“ASO approach (IONIS-HTTRX, Peptide conjugated ASOs) Reduction in HTT mRNA and protein Showed efficacy in a rodent model [70,71]”
MethodTherapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336 · cited 1×
“CRISPR-Cas9 Excision of CAG repeat and, reduction of mutant HTT Showed efficacy in a rodent model [68,69]”
BackgroundMIND diet associated with reduced incidence of Alzheimer's disease
Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., & Aggarwal, N. T. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.009 · Cited by 1,162 · cited 1×
“These types of diet-related studies need further investigation [84,107,126].”
BackgroundLoss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089 · cited 2×
“It is also reported that the higher the CAG expansion, the earlier the onset and the greater the disease severity [12,23].”
BackgroundChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051 · cited 3×
“Treatment with minocycline proved to be neuroprotective, and to improve the disease phenotype [30,42,44].”
BackgroundHuntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., & Hayden, M. R. (1995) · Cell · doi:10.1016/0092-8674(95)90542-1 · Cited by 872
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845 · cited 2×
“Suberoylanilide hydroxamic acid Transcriptional deregulation histone deacetylase inhibitor Showed efficacy in a rodent model [64]”
BackgroundTrehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N. R., Doi, H., Kurosawa, M., Nekooki, M., & Nukina, N. (2004) · Nature Medicine · doi:10.1038/nm985 · Cited by 782 · cited 1×
“Congo red and Trehalose Aggregation Showed efficacy in a rodent model [46,49]”
BackgroundKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770 · cited 2×
“Therefore, the injection of ASOs into the cerebrospinal fluid (CSF) results in ubiquitous delivery of drugs and suppresses the production of mHTT [70] (Table 1).”
BackgroundMethodTargeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708 · cited 4×
“In a recent study of phase I–IIa trial, HTTRx lessened the concentration of mutant HTT in CSF of HD patients.”
BackgroundInfluentialFerrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 693
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · cited 4×
“miRNA Silence HTT Testing in rodent and nonhuman primates [6,72]”
BackgroundMethodInfluentialGraham, R. K., Deng, Y., Slow, E. J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2006.04.026 · Cited by 651 · cited 2×
“Antiapoptotic drug Cleave mHTT Effective in mice model [82,83]”
BackgroundThe Biochemistry of n-3 Polyunsaturated Fatty Acids
Jump, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100062200 · Cited by 636 · cited 1×
“Ethyl-EPA is a derivative of the n-3 polyunsaturated fatty acid EPA, which binds to the peroxisome proliferator-activated receptor of mitochondria [92].”
BackgroundNiewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Kremer, B., Goldberg, P., Andrew, S. E., Theilmann, J., Telenius, H., Zeisler, J., Squitieri, F., Lin, B., Bassett, A., Almqvist, E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405193302001 · Cited by 602 · cited 1×
“reported the largest expansion of 121 trinucleotides [24].”
BackgroundSarkar, S., Ravikumar, B., Floto, R. A., & Rubinsztein, D. C. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.110 · Cited by 578
Wellington, C. L., Ellerby, L. M., Hackam, A. S., Margolis, R. L., Trifiro, M. A., Singaraja, R., McCutcheon, K., Salvesen, G. S., Propp, S. S., Bromm, M., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.9158 · Cited by 562 · cited 2×
“Caspase cleavage (mainly caspase-3 and -6) occur in mHTT [83].”
BackgroundRole of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines, R. M., Boyd, J. D., Ko, R. W. Y., Vasuta, O. C., Graham, R. K., Hayden, M. R., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.008 · Cited by 517
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
Sánchez, I., Mahlke, C., & Yuan, J. (2003) · Nature · doi:10.1038/nature01301 · Cited by 503 · cited 1×
“Congo red and Trehalose Aggregation Showed efficacy in a rodent model [46,49]”
BackgroundGardian, G., Browne, S. E., Choi, D.-K., Klivenyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B., Ratan, R. R., Ferrante, R. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410210200 · Cited by 456 · cited 2×
“Sodium phenylbutyrate Transcriptional deregulation histone deacetylase inhibitor Showed efficacy in a rodent model [62]”
BackgroundOkamoto, S.-I., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2056 · Cited by 436
Becher, M. W., Kotzuk, J. A., Sharp, A. H., Davies, S. W., Bates, G. P., Price, D. L., & Ross, C. A. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0168 · Cited by 433 · cited 1×
“It is the principal factor for the manifestation of HD because aggregates are never a remarkable feature in the brain of normal subjects [26,27].”
BackgroundGlutamine and glutamate as vital metabolites
Newsholme, P., Lima, M. M. R., Procopio, J., Pithon-Curi, T. C., Doi, S. Q., Bazotte, R. B., & Curi, R. (2003) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2003000200002 · Cited by 414
Ehrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M., Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl210 · Cited by 414
Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3
Rigamonti, D., Bauer, J. H., De-Fraja, C., Conti, L., Sipione, S., Sciorati, C., Clementi, E., Hackam, A., Hayden, M. R., Li, Y., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03705.2000 · Cited by 405
Congo red and protein aggregation in neurodegenerative diseases
Frid, P., Anisimov, S. V., & Popovic, N. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.001 · Cited by 402
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92087 · Cited by 399 · cited 2×
“CRISPR-Cas9 Excision of CAG repeat and, reduction of mutant HTT Showed efficacy in a rodent model [68,69]”
BackgroundTherapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391 · cited 1×
“It was neuroprotective in R6/2 mice, delaying motor deficit, atrophy, and inclusion, and extending survival [90,91].”
BackgroundHuntington's disease: underlying molecular mechanisms and emerging concepts
Labbadia, J., & Morimoto, R. I. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.05.003 · Cited by 369
Bachoud-Lévi, A.-C., Gaura, V., Brugières, P., Lefaucheur, J.-P., Boissé, M.-F., Maison, P., Baudic, S., Ribeiro, M.-J., Bourdet, C., Remy, P., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70381-7 · Cited by 358
In vivo newly translated polypeptides are sequestered in a protected folding environment
Thulasiraman, V. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.85 · Cited by 349 · cited 2×
“TRiC (CCT1-CCT8 subunit) is an example of chaperonin which is involved in the folding of about 9–15% of the normal proteins [77] and inhibits aggregation of mHTT [78].”
BackgroundBoudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339 · cited 2×
“In the animal models (R6/1, R62, N171-82Q, RAT AAV-HD70d) of HD, siRNA, shRNA, and miRNA treatments have been used to reduce neuropathology and improve motor function [6,72,104].”
BackgroundMethodHay, D. G. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh144 · Cited by 327
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., Smith, K. M., & Ferrante, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606373103 · Cited by 325 · cited 2×
“Mithramycin and chromomycin Transcriptional deregulation G-C-rich DNA binding antibiotic Showed efficacy in a rodent model [65]”
BackgroundCreatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 3×
“Creatine (with antioxidant properties) reduced serum levels of 8-hydroxy-2′-deoxyguanosine (8-OH-2′-dG) in HD patients [85,86] and is safe and tolerable at a dose of 15 g twice daily [87].”
BackgroundMoss, D. J. H., Pardiñas, A. F., Langbehn, D., Lo, K., Leavitt, B. R., Roos, R., Durr, A., Mead, S., Coleman, A., Santos, R. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30161-8 · Cited by 312
CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
Monteys, A. M., Ebanks, S. A., Keiser, M. S., & Davidson, B. L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.010 · Cited by 309
Keene, C. D., Rodrigues, C. M. P., Eich, T., Chhabra, M. S., Steer, C. J., & Low, W. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162362299 · Cited by 306 · cited 1×
“Mice given TUDCA showed less striatal atrophy, apoptosis, and reduced locomotor and sensory-motor defects [148].”
BackgroundTherapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298 · cited 3×
“New work is now underway to identify these molecules and their possible role in the lowering of mutant HTT gene and protein expression [102,123].”
BackgroundCarroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293 · cited 1×
“ASO can ameliorate transcriptional dysregulation and reduce the level of mHTT and improve behavior in the YAC128, YAC18, and BACHD mouse models of HD [114,115].”
BackgroundThomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804249105 · Cited by 291 · cited 2×
“HDACi4b reversed hypoacetylation of the H3 histone subunit that occurs in the presence of mHTT, and mRNA expression was returned to normal levels [63].”
BackgroundTranscriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 268
Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block
Blanpied, T. A., Clarke, R. J., & Johnson, J. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4262-04.2005 · Cited by 251 · cited 1×
“Amantadine is a weak NMDA receptor blocker [140] and increases dopamine release [141].”
BackgroundBDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice
Xie, Y., Hayden, M. R., & Xu, B. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1637-10.2010 · Cited by 236
Borrell-Pages, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27607 · Cited by 236 · cited 1×
“Cysteamine controls oxidation levels through increasing concentration of glutathione, activation of protein catabolism through the hindrance of transglutaminase and induction of heat shock proteins (HSPs) effects [128].”
BackgroundLegleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L. M., & Muchowski, P. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.093708 · Cited by 235
Southwell, A. L., Ko, J., & Patterson, P. H. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4286-09.2009 · Cited by 232 · cited 2×
“Artificial peptides and intrabodies Targeting proline-rich domain of HTT Showed efficacy in a rodent model [66]”
BackgroundYang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Flint Beal, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 231 · cited 1×
“It was neuroprotective in R6/2 mice, delaying motor deficit, atrophy, and inclusion, and extending survival [90,91].”
BackgroundTreatment of Huntington's Disease
Frank, S. (2014) · Neurotherapeutics · doi:10.1007/s13311-013-0244-z · Cited by 230
Sustained effects of nonallele‐specific Huntingtin silencing
Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi‐Carter, R., Hantraye, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21569 · Cited by 216 · cited 1×
“RNAi reduced neuropathology, improved motor behavior and extended viability in HD [102,104,105].”
BackgroundEvans, S. J., Douglas, I., Rawlins, M. D., Wexler, N. S., Tabrizi, S. J., & Smeeth, L. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304636 · Cited by 207 · cited 1×
“HD is a monogenic disease with prevalence of about 1 in 7,500 individuals in the general population [21,22].”
BackgroundMechanism of neuroprotection by trehalose: controversy surrounding autophagy induction
Lee, H.-J., Yoon, Y.-S., & Lee, S.-J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0749-9 · Cited by 194
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Garriga-Canut, M., Agustín-Pavón, C., Herrmann, F., Sánchez, A., Dierssen, M., Fillat, C., & Isalan, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206506109 · Cited by 194 · cited 2×
“ZFPs reduce mHTT expression without affecting the expression of other genes/wild-type HTT [67,102,107].”
BackgroundMutant huntingtin is present in neuronal grafts in huntington disease patients
Cicchetti, F., Lacroix, S., Cisbani, G., Vallières, N., Saint‐Pierre, M., St‐Amour, I., Tolouei, R., Skepper, J. N., Hauser, R. A., Mantovani, D., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24174 · Cited by 193
Hammond, S. M., Hazell, G., Shabanpoor, F., Saleh, A. F., Bowerman, M., Sleigh, J. N., Meijboom, K. E., Zhou, H., Muntoni, F., Talbot, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605731113 · Cited by 193 · cited 1×
“The injection of ASOs (conjugated with peptides), produced wide CNS distribution and longer life span in the spinal muscular atrophy (SMA) mouse model [116].”
BackgroundDopamine and Glutamate in Huntington's Disease: A Balancing Act
André, V. M., Cepeda, C., & Levine, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00134.x · Cited by 189
Giampà, C., Laurenti, D., Anzilotti, S., Bernardi, G., Menniti, F. S., & Fusco, F. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013417 · Cited by 184
Armstrong, M. J., & Miyasaki, J. M. (2012) · Neurology · doi:10.1212/wnl.0b013e318263c443 · Cited by 180
Riluzole in Huntington's disease: a 3‐year, randomized controlled study
Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21181 · Cited by 176 · cited 2×
“Riluzole Glutamate release inhibitor Does not show efficacy in human trails [31]”
BackgroundSüssmuth, S. D., Haider, S., Landwehrmeyer, G. B., Farmer, R., Frost, C., Tripepi, G., Andersen, C. A., Di Bacco, M., Lamanna, C., Diodato, E., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12512 · Cited by 175
AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23616 · Cited by 175
Constitutive Upregulation of Chaperone-Mediated Autophagy in Huntington's Disease
Koga, H., Martinez-Vicente, M., Arias, E., Kaushik, S., Sulzer, D., & Cuervo, A. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3219-11.2011 · Cited by 174
Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk
Fisher, E. R., & Hayden, M. R. (2014) · Movement Disorders · doi:10.1002/mds.25717 · Cited by 173 · cited 1×
“HD is a monogenic disease with prevalence of about 1 in 7,500 individuals in the general population [21,22].”
BackgroundCurrent Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Coppen, E. M., & Roos, R. A. C. (2016) · Drugs · doi:10.1007/s40265-016-0670-4 · Cited by 173 · cited 1×
“Currently, a phase III trial comparing TBZ with olanzapine and tiapridal is under evaluation [39].”
Backgroundde Yebenes, J. G., Landwehrmeyer, B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., Saft, C., Magnet, M. K., Sword, A., Rembratt, Å., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70233-2 · Cited by 171
Lamotrigine: A Review of its Use in Bipolar Disorder
Goldsmith, D. R., Wagstaff, A. J., Ibbotson, T., & Perry, C. M. (2003) · Drugs · doi:10.2165/00003495-200363190-00009 · Cited by 171 · cited 1×
“Lamotrigine is an antiepileptic drug and decreases glutamate release by blocking voltage-gated sodium channels [143,144].”
BackgroundDi Pardo, A., Maglione, V., Alpaugh, M., Horkey, M., Atwal, R. S., Sassone, J., Ciammola, A., Steffan, J. S., Fouad, K., Truant, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114502109 · Cited by 170
The role of dopamine in huntington's disease
Cepeda, C., Murphy, K. P. S., Parent, M., & Levine, M. S. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63425-2.00010-6 · Cited by 170
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Brück, W., Pförtner, R., Pham, T., Zhang, J., Hayardeny, L., Piryatinsky, V., Hanisch, U.-K., Regen, T., van Rossum, D., Brakelmann, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1009-1 · Cited by 168
Ratovitski, T., Guček, M., Jiang, H., Chighladze, E., Waldron, E., D'Ambola, J., Hou, Z., Liang, Y., Poirier, M. A., Hirschhorn, R. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804813200 · Cited by 168
Kalisman, N., Adams, C. M., & Levitt, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119472109 · Cited by 167 · cited 2×
“TRiC (CCT1-CCT8 subunit) is an example of chaperonin which is involved in the folding of about 9–15% of the normal proteins [77] and inhibits aggregation of mHTT [78].”
BackgroundStanek, L. M., Sardi, S. P., Mastis, B., Richards, A. R., Treleaven, C. M., Taksir, T., Misra, K., Cheng, S. H., & Shihabuddin, L. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.200 · Cited by 162
Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine
Verhagen Metman, L., Morris, M. J., Farmer, C., Gillespie, M., Mosby, K., Wuu, J., & Chase, T. N. (2002) · Neurology · doi:10.1212/wnl.59.5.694 · Cited by 162 · cited 1×
“Amantadine reduces dyskinesias in HD, without provoking parkinsonism [142].”
BackgroundTherapeutic approaches to Huntington disease: from the bench to the clinic
Caron, N. S., Dorsey, E. R., & Hayden, M. R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.133 · Cited by 162 · cited 2×
“New work is now underway to identify these molecules and their possible role in the lowering of mutant HTT gene and protein expression [102,123].”
BackgroundCreatine supplementation in Huntington’s disease: A placebo-controlled pilot trial
Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., & Dom, R. (2003) · Neurology · doi:10.1212/01.wnl.0000090629.40891.4b · Cited by 161 · cited 2×
“In another controlled study, creatine (5 g/day; 1 year) treatment resulted in better muscle function capacity in patients with neuromuscular disease b t did not show improvements in neuro uscular f nction and the cognitive status of stage I–III HD patien s [88].”
BackgroundEkman, F. K., Ojala, D. S., Adil, M. M., Lopez, P. A., Schaffer, D. V., & Gaj, T. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.009 · Cited by 159
Franich, N. R., Fitzsimons, H. L., Fong, D. M., Klugmann, M., During, M. J., & Young, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.50 · Cited by 157 · cited 3×
“miRNA Silence HTT Testing in rodent and nonhuman primates [6,72]”
BackgroundMethod† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 152
Martin, D. S. D., Lonergan, P. E., Boland, B., Fogarty, M. P., Brady, M., Horrobin, D. F., Campbell, V. A., & Lynch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205289200 · Cited by 151 · cited 1×
“inhibiting caspase and reducing mitochondrial damage by reducing the activity of the c-Jun N-terminal kinase (JNK) pathway [93,94].”
BackgroundBiological and clinical manifestations of juvenile Huntington’s disease: A retrospective analysis
Fusilli, C., Migliore, S., Mazza, T., Consoli, F., De Luca, A., Barbagallo, G., Ciammola, A., Gatto, E. M., Cesarini, M., Etcheverry, J. L., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30294-1 · Cited by 148
Glutamate Uptake is Reduced in Prefrontal Cortex in Huntington’s Disease
Hassel, B., Tessler, S., Faull, R. L. M., & Emson, P. C. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9463-1 · Cited by 145
Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 144
Jia, H., Kast, R. J., Steffan, J. S., & Thomas, E. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds379 · Cited by 143
Heng, M. Y., Detloff, P. J., Wang, P. L., Tsien, J. Z., & Albin, R. L. (2008) · Nature Precedings · doi:10.1523/jneurosci.5599-08.2009 · Cited by 143
Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial
Puri, B. K., Leavitt, B. R., Hayden, M. R., Ross, C. A., Rosenblatt, A., Greenamyre, J. T., Hersch, S., Vaddadi, K. S., Sword, A., Horrobin, D. F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000169025.09670.6d · Cited by 142 · cited 9×
“In another controlled study, creatine (5 g/day; 1 year) treatment resulted in better muscle function capacity in patients with neuromuscular disease but did not show improvements in neuromuscular function and the cognitive status of stage I–III HD patients [88].”
MethodInfluentialSymptomatic Treatment of Huntington Disease
Adam, O. R., & Jankovic, J. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.008 · Cited by 141
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A., McDermott, M., Kieburtz, K., de Blieck, E. A., Beal, F., Marder, K., Ross, C., Shoulson, I., Gilbert, P., Mallonee, W. M., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139 · cited 1×
“CoQ10 Mitochondrial dysfunction Attained futility in human trial [58]”
BackgroundBouchard, J., Truong, J., Bouchard, K., Dunkelberger, D., Desrayaud, S., Moussaoui, S., Tabrizi, S. J., Stella, N., & Muchowski, P. J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4008-12.2012 · Cited by 133
Oligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & Aronin, N. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 132
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
Wild, E. J., & Tabrizi, S. J. (2014) · Movement Disorders · doi:10.1002/mds.26007 · Cited by 130
Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C. A., Ye, K., & Duan, W. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt098 · Cited by 129
A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
The Huntington Study Group HART Investigators (2013) · Movement Disorders · doi:10.1002/mds.25362 · Cited by 127
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells
Quintanilla, R. A., Jin, Y. N., Fuenzalida, K., Bronfman, M., & Johnson, G. V. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804291200 · Cited by 124
Ratni, H., Karp, G. M., Weetall, M. L., Naryshkin, N. A., Paushkin, S. V., Chen, K. S., McCarthy, K. D., Qi, H., Turpoff, A., Woll, M. G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00459 · Cited by 123 · cited 1×
“In the SMA mouse model, the treatment of RG7800 showed a dose-dependent increase in SMN protein levels [121].”
MethodZádori, D., Nyíri, G., Szőnyi, A., Szatmári, I., Fülöp, F., Toldi, J., Freund, T. F., Vécsei, L., & Klivènyi, P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0573-6 · Cited by 120
Modulation of nucleosome dynamics in Huntington's disease
Stack, E. C., Del Signore, S. J., Luthi-Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S., Goodrich, S., Markey, A. L., Cormier, K., Hagerty, S. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm064 · Cited by 120 · cited 1×
“Treatments with mithramycin and chromomycin (anthracyclin derivatives) promote epigenetic histone modifications in cultured R6/2 and N171-82Q transgenic cell lines, providing a basis for clinical trials for HD [65,98,99].”
BackgroundNeuroprotective Effect of Eicosapentaenoic Acid in Hippocampus of Rats Exposed to γ-Irradiation
Lonergan, P. E., Martin, D. S. D., Horrobin, D. F., & Lynch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202387200 · Cited by 119
Wang, H., Lim, P. J., Yin, C., Rieckher, M., Vogel, B. E., & Monteiro, M. J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl017 · Cited by 118 · cited 2×
“However, its overexpression did not improve motor symptoms, and did not change the amount of aggregates in the striatum [75,76].”
BackgroundMethodAmyloid-like inclusions in Huntington’s disease
McGowan, D., van Roon‐Mom, W., Holloway, H., Bates, G. P., Mangiarini, L., Cooper, G. J. S., Faull, R. L. M., & Snell, R. G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00391-2 · Cited by 118
Crooke, S. T., Baker, B. F., Kwoh, T. J., Cheng, W., Schulz, D. J., Xia, S., Salgado, N., Bui, H.-H., Hart, C. E., Burel, S. A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.136 · Cited by 117 · cited 5×
“However, ASO delivery has some side effects, like thrombocytopenia which was observed in some human trials of ASOs [113].”
BackgroundInfluentialHuntingtin promotes mTORC1 signaling in the pathogenesis of Huntington’s disease
Pryor, W. M., Biagioli, M., Shahani, N., Swarnkar, S., Huang, W.-C., Page, D. T., MacDonald, M. E., & Subramaniam, S. (2014) · Science Signaling · doi:10.1126/scisignal.2005633 · Cited by 116
Schiefer, J., Sprünken, A., Puls, C., Lüesse, H., Milkereit, A., Milkereit, E., Johann, V., & Kosinski, C. M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.005 · Cited by 115
Minocycline in Huntington's disease: A pilot study
Thomas, M., Ashizawa, T., & Jankovic, J. (2004) · Movement Disorders · doi:10.1002/mds.20018 · Cited by 111 · cited 2×
“Minocycline Caspase-dependent and independent neurodegenerative pathway Inhibits caspase-1 and -3 mRNA upregulation, and decreases inducible nitric oxide synthetase activity [42,44,45]”
BackgroundReilmann, R., McGarry, A., Grachev, I. D., Savola, J.-M., Borowsky, B., Eyal, E., Gross, N., Langbehn, D., Schubert, R., Wickenberg, A. T., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30391-0 · Cited by 111
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
Claassen, D. O., Carroll, B., Boer, L. M. D., Wu, E. Q., Ayyagari, R., Gandhi, S. K., & Stamler, D. A. (2017) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-017-0051-5 · Cited by 110 · cited 1×
“In indirect treatment comparison studies, deutetrabenazine was found to have a favorable tolerability profile compared to tetrabenazine [41].”
BackgroundNeuroprotection in Huntington??s disease: a 2-year study on minocycline
Bonelli, R. M., H??dl, A. K., Hofmann, P., & Kapfhammer, H.-P. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00004 · Cited by 108 · cited 3×
“Treatment with minocycline proved to be neuroprotective, and to improve the disease phenotype [30,42,44].”
BackgroundChopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W., Waldmeier, P., Housman, D. E., Kazantsev, A., Young, A. B., & Hersch, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707842104 · Cited by 108 · cited 2×
“Compound C2–8 Aggregation Showed efficacy in a rodent model [53]”
BackgroundGroves, M., van Duijn, E., Anderson, K., Craufurd, D., Edmondson, M. C., Goodman, N., van Kammen, D. P., & Goodman, L. (2011) · PLoS Currents · doi:10.1371/currents.rrn1259 · Cited by 102
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Triheptanoin improves brain energy metabolism in patients with Huntington disease
Adanyeguh, I. M., Rinaldi, D., Henry, P.-G., Caillet, S., Valabregue, R., Durr, A., & Mochel, F. (2015) · Neurology · doi:10.1212/wnl.0000000000001214 · Cited by 101 · cited 1×
“Triheptanoin is a triglyceride that reverses the metabolic defects in HD by supplying substrates to the Krebs cycle [138].”
BackgroundNithianantharajah, J., & Hannan, A. J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.043 · Cited by 100
Barker, R., Mason, S., Harrower, T., Swain, R. A., Ho, A. K., Sahakian, B. J., Mathur, R., Elneil, S., Thornton, S., Hurelbrink, C. B., et al. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302441 · Cited by 100
Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases
Aylward, E., Liu, D., Nopoulos, P., Ross, C. A., Pierson, R. K., Mills, J. A., Long, J. D., & Paulsen, J. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.030 · Cited by 100
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease
Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., & Gerlach, M. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_14 · Cited by 98 · cited 2×
“Memantine N-methyl-D-aspartate (NMDA) receptor inhibitor Demonstrated efficacy in human trial [32,33]”
BackgroundPRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D., Doros, G., Gevorkian, S., Malarick, K., Reuter, M., Coutu, J.-P., Triggs, T. D., Wilkens, P. J., Matson, W., Salat, D. H., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000187 · Cited by 98 · cited 2×
“Creatine (with antioxidant properties) reduced serum levels of 8-hydroxy-2′-deoxyguanosine (8-OH-2′-dG) in HD patients [85,86] and is safe and tolerable at a dose of 15 g twice daily [87].”
BackgroundGiampà, C., Montagna, E., Dato, C., Melone, M. A. B., Bernardi, G., & Fusco, F. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064037 · Cited by 98
A futility study of minocycline in Huntington's disease
Cudkowicz, M., & The Huntington Study Group DOMINO Investigators (2010) · Movement Disorders · doi:10.1002/mds.23236 · Cited by 97
The CREST-E study of creatine for Huntington disease: A randomized controlled trial
Hersch, S. M., Schifitto, G., Oakes, D., Bredlau, A.-L., Meyers, C. M., Nahin, R., Rosas, H. D., & For the Huntington Study Group CREST-E Investigators and Coordinators (2017) · Neurology · doi:10.1212/wnl.0000000000004209 · Cited by 97
Giorgini, F., Möller, T., Kwan, W., Zwilling, D., Wacker, J. L., Hong, S., Tsai, L.-C. L., Cheah, C. S., Schwarcz, R., Guidetti, P., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708192200 · Cited by 97 · cited 1×
“Treating microglial cells from R6/2 mice with a kynurenine 3-monooxygenase inhibitor (Ro 61–8048) showed dramatically reduced 3-HK levels compared to the vector containing cells [153].”
BackgroundDeep brain stimulation for Huntington's disease: long-term results of a prospective open-label study
González, V., Cif, L., Biolsi, B., Ptacek, S. G., Seychelles, A., Sanrey, E., Descours, I., Coubes, C., de Moura, A. M. R., Corlobé, A., et al. (2014) · Journal of neurosurgery · doi:10.3171/2014.2.jns131722 · Cited by 96
Smith, G. A., Rocha, E. M., McLean, J. R., Hayes, M. A., Izen, S. C., Isacson, O., & Hallett, P. J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu166 · Cited by 95
Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease
Lee, J.-H., Hwang, Y. J., Kim, K. Y., Kowall, N. W., & Ryu, H. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0206-5 · Cited by 94 · cited 1×
“Treatments with mithramycin and chromomycin (anthracyclin derivatives) promote epigenetic histone modifications in cultured R6/2 and N171-82Q transgenic cell lines, providing a basis for clinical trials for HD [65,98,99].”
BackgroundA Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease
Todd, D., Gowers, I., Dowler, S. J., Wall, M. D., McAllister, G., Fischer, D. F., Dijkstra, S., Fratantoni, S. A., van de Bospoort, R., Veenman-Koepke, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087923 · Cited by 93
Fan, J., Gladding, C. M., Wang, L., Zhang, L. Y. J., Kaufman, A. M., Milnerwood, A. J., & Raymond, L. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.019 · Cited by 93
A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease
Kieburtz, K. D., McDermott, M. P., Voss, T., Corey‐Bloom, J., Deuel, L. M., Dorsey, E. R., Factor, S., Geschwind, M. D., Hodgeman, K., Kayson, E., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.334 · Cited by 92 · cited 1×
“In a short duration trial, latrepirdine promoted cognitive improvement (MMSE) in mild to moderate HD patients [11,139].”
BackgroundDau, A., Gladding, C. M., Sepers, M. D., & Raymond, L. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.013 · Cited by 92
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Aguiar, S. P., van der Gaag, B., & Cortese, F. A. B. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0101-9 · Cited by 92
Paroxetine retards disease onset and progression in Huntingtin mutant mice
Duan, W., Guo, Z., Jiang, H., Ladenheim, B., Xu, X., Cadet, J. L., & Mattson, M. P. (2004) · Annals of Neurology · doi:10.1002/ana.20075 · Cited by 91
Tetrabenazine is neuroprotective in Huntington's disease mice
Wang, H., Chen, X., Li, Y., Tang, T.-S., & Bezprozvanny, I. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-18 · Cited by 90
Chiang, M.-C., Lee, Y.-C., Huang, C.-L., & Chern, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413279200 · Cited by 89
Self-citationSodium phenylbutyrate in Huntington's disease: A dose‐finding study
Hogarth, P., Lovrecic, L., & Krainc, D. (2007) · Movement Disorders · doi:10.1002/mds.21632 · Cited by 89 · cited 1×
“A dose-response study highlighted that sodium phenylbutyrate was safe, secure, effective and well-tolerable in HD patients [97].”
BackgroundConsoli, A., Cohen, J. P., Bodeau, N., Guinchat, V., Wachtel, L. E., & Cohen, D. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0320-7 · Cited by 88
Minocycline for Huntington’s disease: An open label study
Bonelli, R. M., Heuberger, C., & Reisecker, F. (2003) · Neurology · doi:10.1212/01.wnl.0000049936.85487.7a · Cited by 86 · cited 2×
“Minocycline is a tetracycline analog and can cross the blood–brain barrier (BBB) and inhibits the expression of caspase-3 and caspase-1 [42,43].”
BackgroundPridopidine activates neuroprotective pathways impaired in Huntington Disease
Geva, M., Kusko, R. L., Soares, H. D., Fowler, K. D., Birnberg, T., Barash, S., Wagner, A. M., Fine, T., Lysaght, A. C., Weiner, B., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw238 · Cited by 85
Sari, Y., Prieto, A. L., Barton, S. J., Miller, B. R., & Rebec, G. V. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-62 · Cited by 84
Measures of growth in children at risk for Huntington disease
Lee, J. K., Mathews, K., Schlaggar, B., Perlmutter, J., Paulsen, J. S., Epping, E., Burmeister, L., & Nopoulos, P. (2012) · Neurology · doi:10.1212/wnl.0b013e3182648b65 · Cited by 84
Ehrnhoefer, D. E., Martin, D. D. O., Schmidt, M. E., Qiu, X., Ladha, S., Caron, N. S., Skotte, N. H., Nguyen, Y. T. N., Vaid, K., Southwell, A. L., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0518-0 · Cited by 82 · cited 1×
“Intermittent fasting promotes autophagy and cleared the mHTT [127].”
BackgroundGenetics of Huntington disease
Nance, M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00001-8 · Cited by 82 · cited 1×
“It is also reported that the higher the CAG expansion, the earlier the onset and the greater the disease severity [12,23].”
BackgroundA randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
Reilmann, R., Rouzade‐Dominguez, M., Carsten Saft, C., Süßmuth, S. D., Priller, J., Rosser, A., Rickards, H. E., Schöls, L. J., Pezous, N., Gasparini, F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26174 · Cited by 81 · cited 2×
“AFQ056 The antagonist for glutamate receptor 5 Showed no improvement in chorea in a clinical trial [79]”
BackgroundSamaranch, L., Blits, B., San Sebastian, W., Hadaczek, P., Bringas, J., Sudhakar, V, Macayan, M., Pivirotto, P. J., Petry, H., & Bankiewicz, K. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.14 · Cited by 80
The therapeutic role of creatine in Huntington's disease
Ryu, H., Rosas, H. D., Hersch, S. M., & Ferrante, R. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.008 · Cited by 79 · cited 2×
“Creatine (with antioxidant properties) reduced serum levels of 8-hydroxy-2′-deoxyguanosine (8-OH-2′-dG) in HD patients [85,86] and is safe and tolerable at a dose of 15 g twice daily [87].”
BackgroundKilloran, A., & Biglan, K. (2014) · Movement Disorders · doi:10.1002/mds.26014 · Cited by 76
Risk factors for the onset and progression of Huntington disease
Chao, T.-K., Hu, J. Y., & Pringsheim, T. M. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.01.005 · Cited by 76
Squitieri, F., Pardo, A. D., Favellato, Μ., Amico, E., Maglione, V., & Frati, L. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12604 · Cited by 75 · cited 2×
“High level of pridopidine is found in brain-derived neurotrophic factor (BDNF) and diminishes mHTT aggregate size and improved motor performance in R6/2 mice [135,136].”
BackgroundBrief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice
Simmons, D. A., Mehta, R. A., Lauterborn, J. C., Gall, C. M., & Lynch, G. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.015 · Cited by 75
Squitieri, F., Orobello, S., Cannella, M., Martino, T., Romanelli, P., Giovacchini, G., Frati, L., Mansi, L., & Ciarmiello, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1103-3 · Cited by 74
Huntington’s Disease: Relationship Between Phenotype and Genotype
Sun, Y., Zhang, Y.-B., & Wu, Z. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9662-8 · Cited by 74
Mao, Z., Choo, Y. S., & Lesort, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04686.x · Cited by 74 · cited 2×
“Cystamine and mitochondrial permeability transition pore blockers Mitochondrial dysfunction Showed efficacy in a rodent model [60]”
BackgroundRijsketic, D. R., Wu, L., Wu, J., Kim, D. B., Rammes, G., Geva, M., Hayden, M. R., & Борисович, Б. И. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.022 · Cited by 73 · cited 1×
“Pridopidine is a modulator of the dopamine 2 receptor [130] and activates the sigma-1 receptor [131].”
BackgroundHuntington's disease: An update of therapeutic strategies
Kumar, A., Singh, S. K., Kumar, V., Kumar, D., Agarwal, S., & Rana, M. K. (2014) · Gene · doi:10.1016/j.gene.2014.11.022 · Cited by 70 · cited 5×
“Energy metabolism deficits and neuronal degeneration are hallmarks of HD, so treatment with meclizine is a potential strategy, especially since it crosses the BBB [20,61] (Table 1 and Figure 2).”
BackgroundInfluentialSelf-citationPineda, J. R., Canals, J. M., Bosch, M., Adell, A., Mengod, G., Artigas, F., Ernfors, P., & Alberch, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03047.x · Cited by 69 · cited 1×
“High level of pridopidine is found in brain-derived neurotrophic factor (BDNF) and diminishes mHTT aggregate size and improved motor performance in R6/2 mice [135,136].”
BackgroundGarcia-Miralles, M., Hong, X., Tan, L. J., Caron, N. S., Huang, Y., To, X. V., Lin, R. Y., Franciosi, S., Papapetropoulos, S., Hayardeny, L., et al. (2016) · Scientific Reports · doi:10.1038/srep31652 · Cited by 66 · cited 1×
“Laquinimod ameliorates myelination deficiency and behavioral deficits in the YAC128 mouse model of HD [150,151].”
BackgroundStanek, L. M., Yang, W., Angus, S., Sardi, P. S., Hayden, M. R., Hung, G. H., Bennett, C. F., Cheng, S. H., & Shihabuddin, L. S. (2013) · Journal of Huntington's Disease · doi:10.3233/jhd-130057 · Cited by 66 · cited 1×
“ASO can ameliorate transcriptional dysregulation and reduce the level of mHTT and improve behavior in the YAC128, YAC18, and BACHD mouse models of HD [114,115].”
BackgroundA Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease
Frank, S., Ondo, W., Fahn, S., Hunter, C., Oakes, D., Plumb, S., Marshall, F., Shoulson, I., Eberly, S., Walker, F., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180ca77ea · Cited by 66
Klivènyi, P., Ferrante, R. J., Gardian, G., Browne, S. E., Chabrier, P., & Beal, M. F. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.t01-1-01868.x · Cited by 66 · cited 2×
“BN82451 Decreases glutamate release by blocking Na+ channels Showed efficacy in a rodent model [80,81]”
BackgroundBrain structure in juvenile-onset Huntington disease
Tereshchenko, A., Magnotta, V. A., Epping, E. A., Mathews, K. D., Espe‐Pfeifer, P., Martin, E., Dawson, J., Duan, W., & Nopoulos, P. (2019) · Neurology · doi:10.1212/wnl.0000000000007355 · Cited by 66
Mutant huntingtin interacts with -tubulin and disrupts vesicular transport and insulin secretion
Smith, R. A., Bacos, K., Fedele, V., Soulet, D., Walz, H. A., Obermüller, S., Lindqvist, A., Björkqvist, M., Klein, P., Önnerfjord, P., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp336 · Cited by 66
Results of the citalopram to enhance cognition in Huntington disease trial
Beglinger, L. J., Adams, W. H., Langbehn, D., Fiedorowicz, J. G., Jorge, R., Biglan, K., Caviness, J., Olson, B., Robinson, R. G., Kieburtz, K., et al. (2014) · Movement Disorders · doi:10.1002/mds.25750 · Cited by 65
Fernandez-Estevez, M. A., Casarejos, M. J., López Sendon, J., Garcia Caldentey, J., Ruiz, C., Gomez, A., Perucho, J., de Yebenes, J. G., & Mena, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090202 · Cited by 65
Substance abuse may be a risk factor for earlier onset of Huntington disease
Byars, J. A., Beglinger, L. J., Moser, D. J., Gonzalez‐Alegre, P., & Nopoulos, P. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6415-8 · Cited by 64 · cited 1×
“These abuses have more significant associations in females than in males [13,14].”
BackgroundEffect of Trinucleotide Repeats in the Huntington's Gene on Intelligence
Lee, J. K., Conrad, A. L., Epping, E. A., Mathews, K. D., Magnotta, V. A., Dawson, J. D., & Nopoulos, P. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.03.031 · Cited by 63
Huntingtin processing in pathogenesis of Huntington disease.
Qin, Z., & Gu, Z. (2004) · PubMed · Cited by 62
Reilmann, R. (2013) · Movement Disorders · doi:10.1002/mds.25500 · Cited by 62
Levodopa responsive parkinsonism in an adult with Huntington's disease
Racette, B. A., & Perlmutter, J. S. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.577 · Cited by 61
Hu, J., Matsui, M., & Corey, D. R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04975.x · Cited by 61 · cited 1×
“, PNA) enables the selective recognition of the mutant allele and selective inhibition of mHTT expression in human fibroblasts [103].”
BackgroundLee, S., Chu, K., Park, J., Kang, L., Ko, S., Jung, K., & Kim, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.035 · Cited by 59 · cited 2×
“Memantine N-methyl-D-aspartate (NMDA) receptor inhibitor Demonstrated efficacy in human trial [32,33]”
Background(2012) · JAMA Neurology · doi:10.1001/2013.jamaneurol.382 · Cited by 58
An update on Huntington's disease: from the gene to the clinic
Kim, S. D., & Fung, V. S. C. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000116 · Cited by 58
External Globus Pallidus Stimulation Modulates Brain Connectivity in Huntington's Disease
Ligot, N., Krystkowiak, P. C., Simonin, C., Goldman, S., Peigneux, P., Naemen, J. V., Monclus, M., Lacroix, S., Devos, D., Dujardin, K., et al. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.186 · Cited by 55
Kalonia, H., Mishra, J., & Kumar, A. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9315-x · Cited by 54
Self-citationGruber, D., Kühn, A. A., Schönecker, T., Kopp, U. A., Kivi, A., Huebl, J., Lobsien, E., Mueller, B., Schneider, G., & Kupsch, A. R. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1201-7 · Cited by 54
Meclizine is neuroprotective in models of Huntington's disease
Gohil, V. M., Offner, N., Walker, J. A., Sheth, S. A., Fossale, E., Gusella, J. F., MacDonald, M. E., Néri, C., & Mootha, V. K. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq464 · Cited by 53 · cited 5×
“Energy metabolism deficits and neuronal degeneration are hallmarks of HD, so treatment with meclizine is a potential strategy, especially since it crosses the BBB [20,61] (Table 1 and Figure 2).”
BackgroundInfluentialMinocycline in phenotypic models of Huntington's disease
Bantubungi, K., Jacquard, C., Greco, A., Pintor, A., Chtarto, A., Tai, K., Galas, M.-C., Tenenbaum, L., Déglon, N., Popoli, P., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.017 · Cited by 52
Relationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease
Marder, K. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3487 · Cited by 52
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Miniarikova, J., Evers, M. M., & Konstantinova, P. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.002 · Cited by 50
Kletzl, H., Marquet, A., Günther, A., Tang, W., Heuberger, J. A. A. C., Groeneveld, G. J., Birkhoff, W. A. J., Mercuri, E. M., Lochmüller, H., Wood, C. L., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.10.001 · Cited by 49 · cited 1×
“Oral administration of RG7800 in SMA patients increased the functional SMN protein level up to two-fold from baseline [122].”
BackgroundRandomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease
Huntington Study Group TREND-HD Investigators (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.1582 · Cited by 49 · cited 1×
“This suggests that ethyl-EPA needs a longer period before improvement can be observed which might possibly reflect a disease modification [96].”
BackgroundSafren, N., Ayadi, A. E., Chang, L., Terrillion, C. E., Gould, T. D., Boehning, D. F., & Monteiro, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087513 · Cited by 47 · cited 2×
“However, its overexpression did not improve motor symptoms, and did not change the amount of aggregates in the striatum [75,76].”
BackgroundMethodSubstance abuse may hasten motor onset of Huntington disease: Evaluating the Enroll-HD database
Schultz, J. L., Kamholz, J. A., Moser, D. J., Feely, S. M. E., Paulsen, J. S., & Nopoulos, P. (2017) · Neurology · doi:10.1212/wnl.0000000000003661 · Cited by 47 · cited 1×
“These abuses have more significant associations in females than in males [13,14].”
BackgroundCombination of stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice
Cho, I. K., Hunter, C. E., Ye, S., Pongos, A. L. A., & Chan, A. W. S. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0066-7 · Cited by 47 · cited 1×
“The combination of neural progenitor stem cell therapy and RNAi therapy can ameliorate symptoms in mouse models of HD [118].”
BackgroundGarcia‐Miralles, M., Yusof, N. A. B. M., Tan, J. Y., Radulescu, C. I., Sidik, H., Tan, L. J., Belinson, H., Zach, N., Hayden, M. R., & Pouladi, M. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1393-1 · Cited by 45 · cited 1×
“Laquinimod ameliorates myelination deficiency and behavioral deficits in the YAC128 mouse model of HD [150,151].”
BackgroundMenalled, L., Kudwa, A. E., Oakeshott, S., Farrar, A. M., Paterson, N. E., Filippov, I., Miller, S., Kwan, M. Y., Olsen, M., Beltrán, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099520 · Cited by 45 · cited 1×
“Inhibition of transglutaminase is the putative mode of action and is observed in R6/2 and zQ175 mouse models of HD [129].”
BackgroundEthyl‐eicosapentaenoic acid treatment in Huntington's disease: A placebo‐controlled clinical trial
Ferreira, J. J., Rosser, A., Craufurd, D., Squitieri, F., Mallard, N., & Landwehrmeyer, G. B. (2015) · Movement Disorders · doi:10.1002/mds.26308 · Cited by 44 · cited 2×
“Eicosapentaenoic acid (EPA) Mitochondria dysfunction A mixed scenario of positive and negative trial [59]”
BackgroundApoptotic cascades as possible targets for inhibiting cell death in Huntington’s disease
Pattison, L. R., Kotter, M., Fraga, D., & Bonelli, R. M. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0198-8 · Cited by 41 · cited 1×
“Caspase-3 and -6 resistant mice did not develop HD neurodegeneration, indicating that cleavage at these caspase sites plays an important role in neurodegeneration of HD [82,123,124].”
BackgroundClinical experience with risperidone and memantine in the treatment of Huntington's disease.
Cankurtaran, E. Ş., Özalp, E., Soygür, H., & Cakir, A. (2006) · PubMed Central · Cited by 41
Palfi, S., RICHE, D., Brouillet, E., Guyot, M., Mary, V., Wahl, F., Peschanski, M., Stutzmann, J. M., & Hantraye, P. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6520 · Cited by 41 · cited 1×
“Riluzole is a glutamate inhibitor that reduces abnormal movement in amyotrophic lateral sclerosis (ALS) patients [29,30].”
BackgroundModern Genome Editing Technologies in Huntington’s Disease Research
Malankhanova, T. B., Malakhova, A. A., Medvedev, S. P., & Zakian, S. M. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-160222 · Cited by 40 · cited 2×
“These types of diet-related studies need further investigation [84,107,126].”
BackgroundIndoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
Mazarei, G., & Leavitt, B. R. (2015) · Journal of Huntington's Disease · doi:10.3233/jhd-159003 · Cited by 40 · cited 1×
“In HD, an imbalance exists between the neurotoxic products and neuroprotective products and targeting the rate-limiting step of IDO1 could effectively shift the balance toward neuroprotective [152].”
BackgroundMediterranean Diet and Minimizing Neurodegeneration
Sofi, F., Macchi, C., & Casini, A. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0041-7 · Cited by 40 · cited 1×
“Various studies indicate that a Mediterranean-type diet may delay the onset of other neurodegenerative diseases, like AD, PD, dementia and cognitive impairment [125].”
BackgroundTrinucleotide Repeat Disorders
Lutz, R. E. (2007) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.11.006 · Cited by 40 · cited 1×
“Approximately 70% of the variation of the disease is due to expanded CAG repeats, while 13% of the variation is due to polymorphisms in the GRIK2 gene [28].”
Background
Cited by
Eid, R., Arab, N. T. T., & Greenwood, M. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.002 · Cited by 288
Huntington disease: A single-gene degenerative disorder of the striatum
Nopoulos, P. C. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/pnopoulos · Cited by 161
Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients
Pierzynowska, K., Gaffke, L., Cyske, Z., & Węgrzyn, G. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00405-4 · Cited by 32
Effects of NAD+ in Caenorhabditis elegans Models of Neuronal Damage
Lee, Y., Jeong, H., Park, K. H., & Kim, K. W. (2020) · Biomolecules · doi:10.3390/biom10070993 · Cited by 8
Self-citation
Metadata
- Authors
- Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-12
- Volume
- 10
- Issue
- 1
- Pages
- 43
- ISSN
- 2076-3425 (ISSN-L)
- OpenAlex
- W3000473074
- Cited by
- 164
- References
- 227
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.